Plasma Drug Concentrations and Virologic Evaluations after Stopping Treatment with Nonnucleoside Reverse‐Transcriptase Inhibitors in HIV Type 1–Infected Children | Zendy

Tim R. Cressey | Zendy; Hannah Green | Zendy; Saye Khoo | Zendy; JeanMarc Tréluyer | Zendy; Alexandra Compagnucci | Zendy; Yacine Saïdi | Zendy; Marc Lallemant | Zendy; Diana M. Gibb | Zendy; David M. Burger | Zendy

Open Access

Plasma Drug Concentrations and Virologic Evaluations after Stopping Treatment with Nonnucleoside Reverse‐Transcriptase Inhibitors in HIV Type 1–Infected Children

Author(s) -

Tim R. Cressey,

Hannah Green,

Saye Khoo,

JeanMarc Tréluyer,

Alexandra Compagnucci,

Yacine Saïdi,

Marc Lallemant,

Diana M. Gibb,

David M. Burger

Publication year - 2008

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/587657

Subject(s) - nevirapine , efavirenz , medicine , reverse transcriptase inhibitor , regimen , viral load , reverse transcriptase , virology , pharmacology , immunology , virus , biology , antiretroviral therapy , polymerase chain reaction , biochemistry , gene

The optimum strategy for stopping treatment with drugs that have different half-lives in a combination regimen to minimize the risk of selecting drug-resistant viruses remains unknown. We evaluated drug concentrations in plasma, human immunodeficiency virus (HIV) load, and development of drug resistance after a planned treatment interruption of a nonnucleoside reverse-transcriptase inhibitor (NNRTI)-containing regimen in HIV type 1-infected children.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research